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Abstract 
Predictors of Depression in Patients Diagnosed with Cancer and Their Caregivers 
 
Reyna E. Jones, BPhil 
 
University of Pittsburgh, 2020 
 
 
Background: Patients diagnosed with cancer and their caregivers have an increased risk for 
depression compared to the general population. The aims of the present study were to determine 
the rate of depressive symptoms in the clinical range, identify predictors of depression, and to 
determine if depression was a predictor of immune system parameters in both patients and 
caregivers.  
Methods: A secondary analysis of baseline data from two clinical trials was used for the purposes 
of this study. Patients and caregivers completed a battery of questionnaires. Patients were assessed 
on sociodemographic factors, fatigue, perceived stress, and pain levels. Caregivers reported 
measures on sociodemographic factors, quality of life, and sleep quality. Descriptive statistics and 
logistic regression were performed to test the hypotheses.  
Results: Of the 259 patient and caregiver dyads that were included in the analyses, the mean age 
of patients was 64.7 (SD = 10.5), and the majority were Caucasian (92.9%) and female (56.6%). 
The mean age of caregivers was 58.5 (SD = 12.5), and the majority were Caucasian (93.2), female 
(73.7%), and the spouse of the cancer patient (63.5%). The rate of depressive symptoms in the 
clinical range in patients was 37.4% and 36.7% in caregivers. In 35 dyads (15.6%) both the patient 
and caregiver reported depressive symptoms in the clinical range. We found that high levels of 
fatigue ( = -0.116; OR = 0.890; 95% CI, 0.848-0.935; p = <0.001) and perceived stress ( = 0.198; 
OR = 1.219; 95% CI, 1.127-1.318; p = <0.001) were predictive of depressive symptoms in patients. 
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Poor quality of life ( = 0.067 OR = 1.069; 95% CI, 1.040-1.099; p = <0.001) was a significant 
predictor of depressive symptoms in cancer caregivers. We found that depressive symptoms did 
not predict immune system parameters in either patients or caregivers after adjusting for 
sociodemographic factors and psychosocial and behavioral covariates.  
Conclusions: This one of a limited number of studies to examine the predictors of depression for 
patients and caregivers in the context of the dyad. Due to the high rates of depression observed, 
psychosocial interventions designed to target the predictors, for patients and caregivers, is 
recommended.  
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1.0 Introduction 
One of the most common mental health conditions in the United States is depression. 
According to the NIH, in 2017 there were approximately 17.3 million adults that experienced at 
least one episode of major depressive disorder, representing 7.1 percent of adults in the U.S.1 
Depression has a significant, negative impact on quality of life such that depression severity is 
proportional to quality of life deterioration.2 Furthermore, mental health conditions such as 
depression are associated with an increased risk of mortality.3 A meta-analysis of 293 studies 
determined that the overall relative risk of mortality in depressed individuals in comparison to 
individuals without depression was 1.52.4 
Higher rates of depression are common among individuals with chronic physical health 
conditions like cancer. Decades of research have demonstrated the psychological impact of cancer. 
The rates of depression in cancer patients can be highly variable and depend in part on the cancer 
type and stage but are frequently higher in cancer patients than the general population.5, 6 In a study 
which consisted of 10,153 patients diagnosed with various cancer types, researchers reported that 
the prevalence of depression was nearly 13 percent overall.7 However, other studies have reported 
the prevalence of depression and depressive disorders in cancer patients as high as 60 percent.6  
Like in the general population, numerous studies have documented that depression has a 
negative impact on a cancer patient’s quality of life.8, 9 Furthermore, co-morbid depression in 
cancer patients has been associated with worsened pain, poor sleep, and fatigue.10-12 Depression in 
cancer patients is also linked to an increased risk of mortality.13, 14 However, in patients diagnosed 
with cancer, depression has not only an impact on mental and physical health but also an economic 
burden on the patient and health care system. Mausbach et al. found that yearly health care charges 
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for cancer patients suffering from depression were 113% higher than cancer patients without 
depression.15 Furthermore, depressed patients diagnosed with cancer typically pay more for 
increased usage of health care services such as ambulatory care, emergency department usage, 
overnight hospitalizations, and hospital fees.15, 16  
While a cancer diagnosis has a significant impact on the patient’s physical and emotional 
health, it also greatly affects the lives of loved ones providing care. Caregivers experiencing 
emotional strain are at an increased risk for mortality.17 Individuals who fulfill a caregiving role 
are also at an increased risk for mental health disorders.18 In a meta-analytic review of nearly 
22,150 participants, the overall prevalence of depression in cancer caregivers was reported to be 
approximately 42 percent.19 However, depression rates in cancer caregivers often vary and have 
been reported as high as 82.2 percent in familial caregivers.20 Cancer caregivers suffering from 
depression have a lower quality of life.21 As depression has an impact on physical health,  impaired 
quality of life, and increased mortality, it is critical to determine predictors that increase the risk 
of depression in both cancer patients and caregivers so that interventions can be given to improve 
mental and long-term health outcomes in these populations. 
1.1 Predictors of Depression in Patients & Their Caregivers and Link with Immunity 
Sociodemographic factors have been linked to depression in both cancer patients and their 
caregivers. Overall, being female and having lower educational attainment is predictive of 
depression.19, 22, 23 However, males diagnosed with cancer who are either unemployed or unable to 
work due to a disability have previously demonstrated more depressive symptoms than women.22 
Gagiee et al. found that there are no age-related differences in depression levels in the context of 
 8 
cancer patients experiencing pain.24 Yet, among caregivers, researchers have suggested that 
depression could be higher among younger (<57 years of age) caregivers as well as caregivers over 
the age of 65.25, 26 Additionally, other factors such as unemployment, caregiving duration, being 
the spouse of the individual needing care, as well as financial issues, have been associated with 
depression in cancer caregivers.19 
Depression rates also vary among cancer types and cancer stages.6 In particular, individuals 
with advanced cancer have exhibited higher levels of depression.27 Furthermore, cancer-related 
symptoms are also reported to impact emotional health. Spiegel indicated that depressive disorders 
were prevalent among 33 percent of patients reporting higher levels of pain compared to a 
frequency of 13 percent among cancer patients with lower pain levels.28 Fatigue, considered the 
most common symptom of cancer, has also been demonstrated to be significantly associated with 
depression.12, 29 Like pain and fatigue, perceived stress is thought to be a possible risk factor for 
depression.30 Furthermore, according to the National Cancer Institute, patients diagnosed with 
cancer who use proper coping mechanisms to manage their stress have lower levels of 
depression.31 Social support is thought to possibly mediate coping style and is also negatively 
related to depression such that it may buffer high depression levels in cancer patients.32-34  
In contrast, predictors of depression in cancer caregivers are both caregiver and patient-
related. A patient predictor reported to have an effect on caregiver depression is mental health. 
Fleming et al. demonstrated that patient depression levels are correlated to caregiver depression 
levels.35 Poor sleep quality and sleep disturbances have been associated with depression in 
caregivers, particularly familial caregivers of patients with advanced cancer.36, 37 Finally, poor 
social support and caregiver stress also predict depression in caregivers of cancer patients38, 39  
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Developing a better understanding of depression in cancer patients and caregivers is critical 
as depression not only has an impact on mental health but immune functioning and survival. A 
prevailing theory related to depression involves the hypothalamic–pituitary–adrenal (HPA) axis 
which is often dysregulated in cancer patients suffering from depression.40 Depression is thought 
to activate the HPA axis, generating a pro-inflammatory cytokine response.41 In patients diagnosed 
with cancer, depression was previously found to be positively associated with IL-1, IL-6, IL-8, 
and TNF-α and negatively associated with IL-10.42 Among cancer patients, cytokines play a role 
in cancer tumor growth and metastatic spread.43-47 A better understanding of the link between 
depression and cytokines could better inform our understanding of the increased risk for physical 
morbidities and mortality in cancer patients and their caregivers. 
Rates of depression in cancer patients and their caregivers are highly variable across 
various cancer types and are less frequently studied in the context of patients and caregivers facing 
cancers affecting the hepatobiliary or pancreatic system. Thus, we will contribute to the literature 
by reporting the rate of depressive symptoms among patients with this rare cancer type and their 
family caregivers, as well as among dyads in which both individuals have depressive symptoms in 
the clinical range. Understanding the predictors of depression in cancer patients and caregivers 
within this population is also particularly important as both patient and caregiver experience can 
vary among cancer types and impact depression and health differently. Additionally, in many 
studies, predictors of depression are examined independently of each other. However, these 
predictors are often associated with each other. Thus, in this study, we will perform a multivariate 
analysis to examine all predictors simultaneously. In the patient analyses we included fatigue, 
perceived stress, and pain as non-sociodemographic predictors of interest. In caregivers, we 
included quality of life and sleep quality as additional predictors. These predictors were chosen as 
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they have known associations with depression and are components commonly impacted within 
these specific populations.12, 21, 28-30, 37 Practically, these variables were chosen as they were 
included in both clinical trials that were used as part of this proposed study. While many studies 
have examined the link between depression and biomarkers of inflammation, few have included 
sociodemographic and psychosocial covariates that have been previously reported to be related to 
immunity. The cytokines included in the present study were chosen secondary to their link with 
psychosocial factors and association with disease progression in the context of cancer. 41-47 
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2.0 Method 
2.1 Participants 
Patients and caregivers were recruited at a large cancer center. Participants were enrolled 
in one of two randomized controlled trials testing a stepped collaborative care intervention between 
April 2007 to October 2011 (K07CA118576, R21CA127046, and P30CA047904) and December 
2016 to January 2020 (R01CA196953). Inclusion criteria of the patients included: biopsy or 
radiographically proven diagnosis of cancer affecting the hepatobiliary or pancreatic system; (2) 
age 21 years or older; (3) fluency in English; and (4) no evidence of thought disorder, 
hallucinations, or delusions. The inclusion and exclusion criteria for the caregivers were: (1) the 
individual was caring for someone with a diagnosis of cancer, (2) age 21 years or older; (3) fluency 
in English; and (4) no evidence of thought disorder, hallucinations, or delusions. The baseline 
assessment of psychosocial factors and immune system parameters was performed during the first 
year after diagnosis with a mean = 9.53 (SD = 23.23) months after diagnosis. 
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2.2 Instruments 
2.2.1 Demographic Factors (Patients and Caregivers) 
The patients and caregivers completed a questionnaire designed specifically for the 
attainment of sociodemographic information. Sociodemographic data collected included gender, 
age, race, educational level, employment status, and income. 
2.2.2 Depressive Symptoms (Patients and Caregivers) 
The Center for Epidemiologic Studies-Depression (CES-D) is a 20-item, self-report 
questionnaire designed to assess depressive symptoms through questions relating to, for example, 
restlessness, enjoyment in life, and focus.48  Patients and caregivers responded on a 4-point scale. 
High levels of depressive symptoms in the clinical range are indicated by a score of 16 or greater. 
The CES-D has established validity evidence and reliability.48   
2.2.3 Fatigue (Patients) 
Fatigue in cancer patients was measured using the Functional Assessment of Chronic 
Illness Therapy (FACIT) Fatigue Scale which is a 13-item assessment that asks patients to rate 
their fatigue performing daily activities over the past week.  Fatigue levels are measure on a four-
point Likert scale (4 = not at all fatigued to 0 = very much fatigued). A low composite score reflects 
increased levels of fatigue. The instrument has high internal validity and test-retest reliability.49 
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2.2.4 Pain (Patients) 
Pain was measured using the Brief Pain Inventory (BPI) which is a 16-item questionnaire 
designed for cancer patients. Specifically, average pain was determined by asking patients to 
numerically rate their average pain levels on a scale of zero to ten. The BPI has good construct and 
concurrent validity.50 
2.2.5 Sleep Quality (Caregivers) 
The Pittsburgh Sleep Quality Index (PSQI) is a questionnaire that assesses one’s sleep in 
the past month.51 The instrument can be broken into component scores such as subjective sleep 
quality. The questionnaire has reported reliability and validity.51 
2.2.6 Perceived Stress (Patients) 
The Perceived Stress Scale (PSS) is a 14 item self-report questionnaire that focuses on the 
degree to which one finds life unpredictable, uncontrollable, and overloading.52 Patients were 
asked to rate each item in regard to the past month on a 5-point Likert-type. The instrument has 
test-retest reliability and substantial validity evidence.52 
2.2.7 Caregiver Quality of Life (Caregivers) 
The Caregiver Quality of Life Index- Cancer (CQOLC) scale is a 35-item instrument that 
assesses quality of life in cancer caregivers. Caregivers responded on a 5-point scale. A higher 
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total score was indicative of poor quality of life. The instrument is considered to be both reliable 
and valid.53 
2.3 Immunity 
2.3.1 Cytokines (Patients and Caregivers) 
Serum levels of cytokines IL-1α, IL-1β, IL-2, IL-6, and TNFα were measured for both 
patients and caregivers.  To obtain the serum levels, blood was drawn typically between 8 am and 
noon. Red top vacutainer tubes without anticoagulant were used to collect blood samples. After at 
least 30 minutes to allow for clot formation, the blood was processed in a University of Pittsburgh 
laboratory. The serum was processed and stored within four hours and frozen at −80° C. It was 
thawed once and then tested using Luminex. The standard curve range of Millipore multi-plex kit, 
HCYTOMAG-60K for each cytokine was 10,000 to 0.064 pg/ml. Milliplex Analyst 5.1 software 
was used to determine standard curve concentrations and the Minimum Detectable Concentration 
(MinDC). Quality control samples of established concentrations were analyzed with the samples. 
The quality controls were within the acceptable range for all analytes on all analyzed samples. 
2.4 Procedure 
Both studies were approved by the University of Pittsburgh’s Institutional Review Board 
prior to participant enrollment. Following the recommendation of the medical team, the patient 
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and caregiver spoke with a member of the research team about the associated risks and benefits of 
each study. Prior to completing any study questionnaires, written and informed consent was 
obtained for each participant.  
2.5 Data Analytics 
Data was analyzed using SPSS version 25 (IBMCorp, Armonk, NY). Descriptive statistics 
were used in order to determine the prevalence of higher levels of depressive symptoms in patients, 
caregivers, and patient-caregiver dyads. Logistic regression was then utilized to examine which 
constructs were predictive of depression in cancer patients and their caregivers, accounting for 
sociodemographic factors such as gender, race, age, education, and employment status. Finally, 
we also performed logistic regression to test the link between depression and IL-1α, IL-1β, IL-2, 
IL-6, and TNFα after adjusting for gender, race, age, years of education, employment status, and 
other psychosocial and behavioral factors associated with immunity among cancer patients and 
caregivers. 
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3.0 Results 
3.1 Sociodemographic Characteristics and Depressive Symptoms in Patients and 
Caregivers 
A total of 259 patient and caregiver dyads were included in the analyses. The mean age of 
patients was 64.7 (SD = 10.5), and the majority were Caucasian (92.9%) and female (56.6%). The 
mean age of caregivers was 58.5 (SD = 12.5), and the majority were Caucasian (93.2), female 
(73.7%), and the spouse of the cancer patient (63.5%). The rate of depressive symptoms in the 
clinical range among patients was 37.4% and 36.7% in caregivers. In 35 dyads (15.6%), both the 
patient and caregiver reported depressive symptoms in the clinical range. See Appendix Table 1. 
_______________ 
Appendix Table 1 
_______________ 
3.2 Predictors of Depression in Patients Diagnosed with Cancer 
Binary logistic regression was used to test the predictors of depression in patients 
diagnosed with cancer. Predictors in the model included gender, race, age, years of education, 
employment status, fatigue, perceived stress, and pain. We found that high levels of fatigue ( = -
0.116; OR = 0.890; 95% CI, 0.848-0.935; p = <0.001) and perceived stress ( = 0.198; OR = 1.219; 
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95% CI, 1.127-1.318; p = <0.001) were predictive of depressive symptoms in patients. See 
Appendix Table 2. 
_______________ 
Appendix Table 2 
_______________ 
3.3 Predictors of Depression in Caregivers of Those Diagnosed with Cancer  
Binary logistic regression was used to test the predictors of depression in caregivers. 
Predictors in the model included gender, race, age, years of education, employment status, 
caregiver quality of life, and sleep quality. We found that poor quality of life, measured as a higher 
score on the CQOLC instrument ( = 0.067 OR = 1.069; 95% CI, 1.040-1.099; p = <0.001) was 
a significant predictor of depression in cancer caregivers. See Appendix Table 3. 
______________ 
Appendix Table 3 
______________ 
3.4 Depression and Immunity 
Binary logistic regression was used to determine if patient depressive symptoms were 
predictive of the cytokines IL-1α, IL-1β, IL-2, IL-6, and TNFα in separate, multivariate analyses. 
Gender, race, age, years of education, and employment as well as other known predictors of 
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cytokines such as fatigue, perceived stress, and pain were adjusted for in each analysis. After 
adjusting for these factors, we found that depression did not significantly predict IL-1α 
( = − OR = 0.406; 95% CI, 0.158-1.043; p = 0.061), IL-1β ( = − OR = 0.768; 95% 
CI, 0.315-1.869; p = 0.560), IL-2 ( = -0.287 OR = 0.751; 95% CI, 0.281-2.007; p = 0.568), IL-
6 ( = 0.726 OR = 2.067; 95% CI, 0.673-6.354; p = 0.205), or TNFα ( = 0.410 OR = 1.506; 
95% CI, 0.564-4.021; p = 0.413). 
Binary logistic regression was used to test predictors of cytokines in caregivers including 
IL-1α, IL-1β, IL-2, IL-6, and TNFα. Gender, race, age, years of education, employment, caregiver 
quality of life, and sleep quality were adjusted for in each analysis.  We found that depression did 
not significantly predict caregivers’ IL-1α ( = 0.982 OR = 2.669; 95% CI, 0.737-9.658; p = 
0.135), IL-1β ( = 0.529 OR = 1.697; 95% CI, 0.443-6.510; p = 0.440), IL-2 ( = 0.550 OR = 
1.733; 95% CI, 0.335-8.965; p = 0.512), IL-6 ( = 0.137 OR = 1.147; 95% CI, 0.379-3.473; p = 
0.809), or TNFα ( = 1.426 OR = 4.163; 95% CI, 0.428-40.489; p = 0.219). 
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4.0 Discussion 
Depressive symptoms in the clinical range were observed in patients diagnosed with cancer 
and their family caregivers. We found that fatigue and higher perceived stress in patients, as well 
as poor quality of life in cancer caregivers, were most predictive of increased depressive 
symptoms. Several studies establish the relationship between fatigue and depression in cancer 
patients.12, 54 For example, in a study analyzing the relationship between fatigue and depression, 
scientists reported a significant, positive relationship within patients in remission for 
hematological malignancies.54 Previous literature also suggests the positive relationship between 
perceived stress and depression in cancer patients.30 In the context of cancer caregivers, quality of 
life (in part, reflective of burden, disruption to one’s life, and financial concern) has previously 
been shown to be linked with depression such that there is a negative relationship between quality 
of life and depression.19, 55, 56 Our study is different from other studies which analyze predictors of 
depression such that we do not study predictors of depression independent of each other or merely 
adjust for sociodemographic factors.   
Interestingly, neither depressive symptoms in patients diagnosed with cancer or caregivers 
were predictive of immunity. Several studies have suggested a link between depression and pro-
inflammatory cytokines in cancer patients and caregivers. However, depression is often studied 
independently of other factors associated with immunity, or in some cases, is studied adjusting for 
sociodemographic factors only.42 Himmerich et al. suggest, “Even though cytokines are often 
discussed as biomarkers for depression, they have also been shown to be altered in other 
psychiatric disorders. Moreover, many environmental, social, psychological, biological, and 
medical factors are also associated with cytokine changes.”57 These factors should be included in 
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any analyses testing the link between depression and biomarkers of inflammation. In this study, 
we not only accounted for sociodemographic factors but additional predictors of immunity such 
as pain, fatigue, perceived stress, and quality of life. Our findings suggest that other predictors of 
immunity may influence or underlie the previously established link between depression and 
cytokines such that depression is not an independent risk factor for immunity alternations. 
One limitation of this study is the lack of a demographically diverse population of patients 
and caregivers. The majority of patients and caregivers were middle age, Caucasian females. 
Notably, nearly two-thirds of caregivers were female. Ideally, over time, more men could be 
recruited into the studies to enable a better understanding of the role of caregiving in this 
population. However, despite this limitation, previous literature does suggest that women make up 
approximately two-thirds of caregivers, consistent with the rate of female caregivers in these 
studies.58 Furthermore, the studies would ideally be conducted with a racially diverse group of 
patients and caregivers. In addition, assessing various predictors of depression and cytokines in 
various cancer diagnoses and stages is important in establishing the validity of these predictors 
and our findings outside the context of cancers affecting the hepatobiliary and pancreatic system.   
Another limitation of this study was a lack of the same psychosocial predictors included in 
both the patient and caregiver analyses. The aims of the original clinical trials were not to examine 
the predictors of depression and immune system parameters. Therefore including the same 
predictors for both patients and caregivers was not previously planned for the purposes of this 
study. Future studies interested in the predictors of patients and caregiver dyads may consider 
including the same predictors across patients and caregivers. 
In this study, we also used dichotomous outcome variables (e.g. depression and cytokines) 
as opposed to continuous variables in the analysis. One limitation of this approach is that 
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individuals close to the cutpoint on either side would be considered as being dissimilar when they 
are actually more similar with regard to symptoms. However, by using dichotomous variables, we 
obtain more clinically meaningful outcomes that have been shown in prior research to be linked to 
disease progression and mortality. 4, 13, 14, 43-47 Although power is also a consideration as the use of 
continuous variables often results in greater power, even with the use of dichotomous outcomes, 
the power was sufficient to test the hypotheses and therefore is our rationale for using dichotomous 
rather than continuous variables.  Finally, while we propose that fatigue and perceived stress in 
patients, as well as poor quality of life in caregivers, are predictors of depression in this cross-
sectional study, there is a possibility that these factors do not cause depression but rather are the 
result of depression. Thus, longitudinal data collection and analysis in the future is important to 
obtain a better understanding of the directionality of this relationship. 
Despite several limitations, there are multiple strengths to this study. First determining 
predictors of depression among patients and caregivers facing hepatobiliary cancer is particularly 
important as psychological health is less commonly studied in this context. Furthermore, as the 
experience of a cancer diagnosis and caregiving for a loved one with cancer can vary among cancer 
types, it is important to address predictors of depression in cancers affecting the hepatobiliary and 
pancreatic system. The specific finding that perceived stress and fatigue are predictors of 
depression among patients is particularly useful in a clinical setting. Depression has an adverse 
impact on both the patient, family, and the health care system. Thus, developing interventions to 
target fatigue and stress could be useful in managing or decreasing the risk of depression in cancer 
patients.59 In terms of caregiving, finding that poor quality of life is associated with depression 
informs clinicians of the importance of monitoring caregiver psychological health and quality of 
life. Interventions could also be put in place to help caregivers improve their well-being during a 
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typically stressful period in their lives. Finally, our study also informs future research that analyzes 
the link between depression and immunity. We have demonstrated the importance of studying the 
relationship between depression and cytokines in terms of both sociodemographic factors and 
other known predictors of immunity.  
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Appendix A Tables 
 
Appendix Table 1 Sociodemographic Characteristics and Prevalence of Depression in Patients and 
Caregivers 
Characteristics Patients Caregivers 
Age (mean, SD) 64.7 (10.5) 58.5 (12.5) 
Female (n, %) 146 (56.6) 191 (73.7) 
Race (n, %)   
Caucasian 235 (92.9) 234 (93.2) 
Black 14 (5.5) 14 (5.6) 
Asian 4 (1.6) 1 (0.4) 
American Indian - 2 (0.8) 
Years of Education (mean, SD) 13.2 (2.6) 14.4 (6.8) 
Employment Status (n, %)   
Full/Part-Time 80 (32.4) 137 (54.6) 
Unemployed/Disabled 57 (23.1) 25 (10.0) 
Homemaker/Student 35 (14.2) 28 (11.2) 
Retired & Not Employed 75 (30.4) 61 (24.3) 
Income (n, %)   
< $30,000 63 (30.9) 52 (24.3) 
> $30,000 
141 (69.1) 162 (75.7) 
Familial Caregivers (n, %) - 211 (84.1) 
Relationship to Patient (n, &)   
Spouse - 158 (63.5) 
Intimate Partner - 16 (6.4) 
Adult Child - 36 (14.5) 
Siblings - 8 (3.2) 
Other - 31 (12.4) 
Depression (n, %) 95 (37.4) 84 (36.7) 
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Appendix Table 2 Predictors of Depression in Patients 
 
1 Average pain in last week (0-10) 
Appendix Table 3 Predictors of Depression in Caregivers 
  
Factor Beta Standard 
Error 
Odds 
Ratio 
p-value 95% Confidence 
Gender (ref: female) -0.193 0.474 0.824 0.684 0.326 2.087 
Race (ref: Caucasian) -1.600 0.864 0.202 0.064 0.037 1.098 
Age (years) 0.061 0.029 1.062 0.035 1.004 1.124 
Education (years) 0.093 0.094 1.097 0.325 0.912 1.319 
Employment (ref: Full/Part-Time)    0.275   
Unemployed/Disabled 0.594 0.676 1.812 0.379 0.482 6.815 
Homemaker/Student 1.424 0.735 4.154 0.053 0.984 17.528 
Retired & Not Employed 0.152 0.625 1.164 0.808 0.342 3.961 
FACIT Fatigue Scale -0.116 0.025 0.890 <0.001 0.848 0.935 
Perceived Stress 0.198 0.040 1.219 <0.001 1.127 1.318 
Pain1 0.052 0.088 1.053 0.557 0.886 1.251 
Factor Beta Standard 
Error 
Odds 
Ratio 
p-value 95% Confidence 
Gender (ref: female) -0.718 0.536 0.488 0.181 0.171 1.396 
Race (ref: Caucasian) -1.23 0.891 0.292 0.167 0.051 1.674 
Age (years) -0.039 0.021 0.962 0.060 0.924 1.002 
Education (years) -0.166 0.093 0.847 0.076 0.705 1.017 
Employment (ref: Full/Part-Time)    0.386   
Unemployed/Disabled 0.477 0.700 1.611 0.495 0.409 6.353 
Homemaker/Student 1.019 0.697 2.771 0.144 0.707 10.864 
Retired & Not Employed 0.772 0.634 2.164 0.224 0.624 7.502 
Caregiver Quality of Life Index-
Cancer 0.067 0.014 1.069 <0.001 1.04 1.099 
Sleep Quality (ref: Very Good)     0.307   
Fairly Good 0.383 0.678 1.467 0.572 0.388 5.539 
Fairly Bad 1.171 0.735 3.226 0.111 0.764 13.612 
Very Bad 0.700 1.081 2.014 0.517 0.242 16.766 
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